To help labs get the answers they so desperately need, The Dark Intelligence Group has launched the COVID-19 STAT Intelligence Briefings Service.
During this disruptive SARS-CoV-2 pandemic, TDIG has created this free intelligence service with a total focus on COVID-19 and everything labs need to meet the business challenges of the pandemic, including the latest on rapid molecular serology COVID-19 testing, with sources and supply chain updates; How labs are getting paid for COVID-19 by Medicare, Medicaid, and private health plans; and Daily updates on changes to federal regulations and directives from the FDA, CDC, and CMS.
COVID-19 STAT Intelligence Briefings service updates daily. It includes briefings, interviews with leading subject matter experts, podcasts and webinars, plus timely analysis of the daily changes in the pandemic.
It is all actionable information, supplemented with real-time national lab test dashboards fed with data from TDIG partners at XIFIN, Visiun, and hc1.com.
COVID-19 STAT Intelligence Briefings is also introducing twice-weekly conference calls, so attendees can hear updates from nationally known thought leaders and get critical questions answered on managing their laboratories during the SARS-CoV-2 outbreak.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024